High levels of circulating biomarkers associated with poor prognosis in melanoma patients (TNFR2, TGF-alpha, TIMP1, CRP) were recently identified by multiplex technology and described as being part of a valuable formula for overall survival prediction (OS)86. This evidence concerns the gene CRP and melanoma.